StockData
Theriva Biologics, Inc. logo

Theriva Biologics, Inc. (TOVX) stock

TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.14+0.00 (0.00%)

Close on Nov 17, 2026Market cap $6.42MP/E –Yield –

Theriva Biologics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Theriva Biologics's enterprise value was -$3.95M on Nov 11, 2026, against -$4.75M a year earlier. Over the last 5 years it ranged from -$43.23M to $136.17K, with a median of -$15.17M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$3.95M–
2025Dec 31, 2025-$5.36M–
2024Dec 31, 2024-$11.83M–
2023Dec 29, 2023-$23.76M–
2022Dec 30, 2022-$43.23M–
2021Dec 31, 2021-$38.97M–
2020Dec 31, 2020-$1.16M–
2019Dec 31, 2019-$12.92M–
2018Dec 31, 2018-$8.50M-119.9%
2017Dec 29, 2017$42.64M-33.0%
2016Dec 30, 2016$63.61M-63.7%
2015Dec 31, 2015$175.41M+113.8%
2014Dec 31, 2014$82.05M+29.9%
2013Dec 31, 2013$63.17M+19.9%
2012Dec 31, 2012$52.68M+87.7%
2011Dec 30, 2011$28.07M–

More Theriva Biologics figures

See a number that looks wrong?